Patents by Inventor Shie-Liang Hsieh
Shie-Liang Hsieh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230365640Abstract: Disclosed herein is a CLEC2 fusion protein comprising a first polypeptide and a second polypeptide coupled to the upstream of the first polypeptide. According to embodiments of the present disclosure, the first and the second polypeptides respectively comprise the amino acid sequences of SEQ ID NOs: 1 and 2. Also disclosed therein are uses of the CLEC2 fusion protein in treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and treating influenza virus infection.Type: ApplicationFiled: September 29, 2021Publication date: November 16, 2023Applicant: Academia SinicaInventors: Shie-Liang HSIEH, Pei-Shan SUNG
-
Publication number: 20220213188Abstract: Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease (AD), by use of monoclonal antibody, which exhibits a binding affinity to Siglec-3 receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.Type: ApplicationFiled: September 25, 2019Publication date: July 7, 2022Applicant: Academia SinicaInventors: Shie-Liang HSIEH, Pei-Shan SUNG, Ming-Ting HUANG, An-Suei YANG, Chung-Ming YU
-
Patent number: 11142795Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.Type: GrantFiled: March 15, 2018Date of Patent: October 12, 2021Assignee: ACADEMIA SINICAInventors: Shie-Liang Hsieh, Ya-Lang Huang, Tsung-Yu Tsai
-
Publication number: 20210292413Abstract: Disclosed herein is a novel monoclonal antibody exhibiting binding affinity to Siglec-3 receptor. According to the embodiment, the monoclonal antibody is capable of reversing HBV-induced immunosuppression. Accordingly, also disclosed herein are the uses thereof in the treatment and/or prophylaxis of hepatitis B virus (HBV) infection.Type: ApplicationFiled: September 25, 2018Publication date: September 23, 2021Applicant: Academia SinicaInventors: Shie-Liang HSIEH, Tsung-Yu TSAI, An-Suei YANG, Chung-Ming YU, Cheng-Yuan PENG
-
Publication number: 20200010898Abstract: Disclosed herein is a novel use of C-type lectin 18 (CLEC18) in disease prognosis. According to embodiments of the present disclosure, the mRNA or protein level of CLEC18 may serve as an indicator for diagnosing hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg) loss and seroconversion, and/or liver fibrosis.Type: ApplicationFiled: March 15, 2018Publication date: January 9, 2020Applicant: Academia SinicaInventors: Shie-Liang HSIEH, Ya-Lang HUANG, Tsung-Yu TSAI
-
Patent number: 10172919Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.Type: GrantFiled: December 29, 2015Date of Patent: January 8, 2019Assignee: ACADEMIA SINICAInventors: Shie-Liang Hsieh, Yung-Chi Chang, Ming-Ting Huang
-
Patent number: 10011646Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.Type: GrantFiled: August 18, 2016Date of Patent: July 3, 2018Inventors: Shie-Liang Hsieh, Henrich Cheng, Wen-Hung Huang, Chuan-Wen Chiu, Shao-Ji Lin
-
Publication number: 20170360884Abstract: Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.Type: ApplicationFiled: December 29, 2015Publication date: December 21, 2017Applicant: Academia SinicaInventors: Shie-Liang HSIEH, Yung-Chi CHANG, Ming-Ting HUANG
-
Publication number: 20170051038Abstract: Disclosed herein are methods for treating spinal cord injury using recombinant decoy receptor 3 (DcR3) polypeptide. Also disclosed herein are methods for improving the locomotor function recovery of a spinal cord injured subject with a DcR3 polypeptide.Type: ApplicationFiled: August 18, 2016Publication date: February 23, 2017Applicant: Academia SinicaInventors: Shie-Liang Hsieh, Henrich Cheng, Wen-Hung Huang, Chuan-Wen Chiu, Shao-Ji Lin
-
Publication number: 20150369806Abstract: A sensor for detecting molecular interactions between a target and a binding domain by electrochemical impedance spectroscopy. The sensor includes an anodic aluminum oxide barrier layer having a gold-coated array of regularly spaced nano-hemispheres and gold nanoparticles coated with a binding domain attached thereto. Also provided are methods for producing the sensor and for using the sensor to detect the presence of a virus in a sample.Type: ApplicationFiled: June 17, 2015Publication date: December 24, 2015Inventors: GOU-JEN WANG, Shie-Liang Hsieh, Yen-Ting Tung
-
Patent number: 8460669Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.Type: GrantFiled: May 12, 2011Date of Patent: June 11, 2013Assignee: Academia SinicaInventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
-
COMPOSTIONS AND METHODS FOR IDENTIFYING RESPONSE TARGETS AND TREATING FLAVIVIRUS INFECTION RESPONSES
Publication number: 20120213770Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.Type: ApplicationFiled: May 12, 2011Publication date: August 23, 2012Applicant: Academia SinicaInventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen -
Patent number: 7998482Abstract: The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions. Polysaccharide compositions include those isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface.Type: GrantFiled: July 31, 2009Date of Patent: August 16, 2011Assignee: Academia SinicaInventors: Chi-Huey Wong, Shie-Liang Hsieh, Tsui-Ling Hsu, Shih-Chin Cheng, Szu-Ting Chen
-
Patent number: 7943134Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.Type: GrantFiled: March 27, 2008Date of Patent: May 17, 2011Assignee: Academia SinicaInventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
-
Publication number: 20100055096Abstract: The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions. Polysaccharide compositions include those isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface.Type: ApplicationFiled: July 31, 2009Publication date: March 4, 2010Applicant: Academia SinicaInventors: Chi-Huey Wong, Shie-Liang Hsieh, Tsui-Ling Hsu, Shih-Chin Cheng, Szu-Ting Chen
-
Patent number: 7491397Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.Type: GrantFiled: January 10, 2005Date of Patent: February 17, 2009Assignee: National Health Research InstitutesInventors: Pele Choi Sing Chong, Shie-Liang Hsieh
-
Publication number: 20090022735Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.Type: ApplicationFiled: July 28, 2008Publication date: January 22, 2009Applicant: National Health Research InstitutesInventors: Pele Choi Sing Chong, Shie-Liang Hsieh
-
Publication number: 20080292644Abstract: Cellular receptors are identified that induce plasma leakage and other negative effects when infected with flaviviruses, such as dengue virus or Japanese encephamyelitis virus. Using fusion proteins disclosed herein, the receptors to which a pathogen, such as flavivirus, binds via glycan binding are determined. Once the receptors are determined, the effect of binding to a particular receptor may be determined, wherein targeting of the receptors causing a particular symptom may be targeted by agents that interrupt binding of the pathogen to the receptor. Accordingly, in the case of dengue virus and Japanese encephamyelitis virus, TNF-? is released when the pathogen binds to the DLVR1/CLEC5A receptor. Interrupting the DLVR1/CLEC5A receptor with monoclonal antibodies reduced TNF-? secretion without affecting secretion of cytokines responsible for viral clearance thereby increasing survival rates in infected mice from nil to around 50%.Type: ApplicationFiled: March 27, 2008Publication date: November 27, 2008Inventors: Shie-Liang Hsieh, Chi-Huey Wong, Tsui-Ling Hsu, Szu-Ting Chen
-
Publication number: 20080213284Abstract: Isolated polypeptides containing fragments of SARS CoV S protein and functional equivalents thereof. Also disclosed are isolated nucleic acids encoding the polypeptides, related expression vectors, related host cells, related antibodies, and related compositions. Methods of producing the polypeptide, diagnosing infection with a coronavirus, and identifying a test compound for treating infection with a coronavirus are also disclosed.Type: ApplicationFiled: January 10, 2005Publication date: September 4, 2008Inventors: Pele Choi Sing Chong, Shie-Liang Hsieh
-
Publication number: 20070072247Abstract: The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions. Polysaccharide compositions include those isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface.Type: ApplicationFiled: August 31, 2006Publication date: March 29, 2007Applicant: Academia SinicaInventors: Chie-Huey Wong, Shie-Liang Hsieh, Tsui-Ling Hsu, Shih-Chin Cheng, Szu-Ting Chen